Chime Biologics, a China-based contract development and manufacturing organization (CDMO) providing fully-integrated services to support development and manufacturing of complex biologics, has begun operations as an independent and stand-alone biologics CDMO company. With the separation from JHL Biotech complete, Chime Biologics is now focused on delivering biologics CDMO services to its global clients and business partners.
 
“One year ago, we initiated a separation plan to realize a vision of operating as a client dedicated platform bringing our clients’ programs to patients in the most efficient way. Now as a fully independent platform, we can better execute our strategy to deliver client-dedicated CDMO services with the greater quality, speed, efficiency and state of the art capability in the thriving and dynamic biologics market,” said James Huang, executive chairman and chief executive officer, Chime Biologics.
 
Chime Biologics’ state-of-the-art 150,000 square feet facility is located in the Wuhan’s BioLake biotech industry development zone of China (China Optics Valley). As the world’s first GE KuBio facility, it’s environmentally friendly design reduces CO2 emissions and water and energy usage, according to the company. The current facility is equipped with four 2,000 L and two 500 L single-use bioreactors for both clinical and commercial GMP manufacturing, avoiding costly cleaning and sterilization steps and allowing a more efficient manufacturing process. The facility has a clear path to expand the total capacity to 27,000 L by 2022 and 140,000+ L by 2024.
 
The company’s clients include innovative biotech companies and major pharmaceutical companies around the world. With seasoned teams specialized in biologics manufacturing and the state-of-the-art facility, Chime Biologics can solve complex large molecule challenges faced at various stage of development, with track-record of zero failure in manufacturing scale up.
 
Amid the recent coronavirus outbreak, Chime Biologics took immediate actions to support the community and the local government via a string of initiatives. Immediately after closing down of Wuhan city, Chime Biologics donated a wide range of medical materials, including protective gowns, head caps, overshoes, and masks for the frontline usage, to supplement the material shortage due to emergency need. Further, with support from its strategic partner, Chime Biologics donated one million RMB to the China Optics Valley to help fighting the novel coronavirus epidemic.
 
“With its outpouring of support, Chime Biologics believes united efforts will be the key to conquering the disease. While the epidemic prevention and control task is arduous, we believe if we can support and stand by our frontline workers, we will come out of this much stronger. It is with the government leadership and everyone’s support that we will fight this off. Wuhan, Jia You!” said Andrew Ng, chairman and board director, Chime Biologics. “Times like these, fully reinforce our commitment to continue doing what is right in supporting therapeutic advancements for patients and for human health.”